Healthcare provider profile · identity verified

Richard A Smith, D.O.

Psychiatry · TAMPA, FL · NPI 1699903641

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	533	70
Quetiapine Fumarate	Quetiapine Fumarate	301	35
Clonazepam	Clonazepam	262	40
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	257	36
Lorazepam	Lorazepam	247	32
Trazodone Hcl	Trazodone Hcl	208	34
Diazepam	Diazepam	175	25
Sertraline Hcl	Sertraline Hcl	173	22
Fluoxetine Hcl	Fluoxetine Hcl	171	20
Zolpidem Tartrate	Zolpidem Tartrate	165	32
Bupropion Xl	Bupropion Hcl	162	24
Olanzapine	Olanzapine	128	22
Escitalopram Oxalate	Escitalopram Oxalate	126	28
Oxcarbazepine	Oxcarbazepine	121	16
Temazepam	Temazepam	119	20
Mirtazapine	Mirtazapine	114	17
Buspirone Hcl	Buspirone Hcl	93	17
Benztropine Mesylate	Benztropine Mesylate	89	16
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	89	13
Lamotrigine	Lamotrigine	89	17
Modafinil	Modafinil	89	15
Trintellix	Vortioxetine Hydrobromide	84	14
Duloxetine Hcl	Duloxetine Hcl	83	14
Memantine Hcl	Memantine Hcl	82	14
Risperidone	Risperidone	82	13
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	80	suppressed
Propranolol Hcl	Propranolol Hcl	74	11
Paroxetine Hcl	Paroxetine Hcl	69	15
Nortriptyline Hcl	Nortriptyline Hcl	67	15
Topiramate	Topiramate	55	suppressed
Lithium Carbonate	Lithium Carbonate	54	12
Ziprasidone Hcl	Ziprasidone Hcl	51	suppressed
Prazosin Hcl	Prazosin Hcl	50	suppressed
Rexulti	Brexpiprazole	50	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	49	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	49	suppressed
Paliperidone Er	Paliperidone	49	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	47	suppressed
Gabapentin	Gabapentin	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	43	suppressed
Divalproex Sodium Er	Divalproex Sodium	43	suppressed
Lurasidone Hcl	Lurasidone Hcl	42	suppressed
Invega Sustenna	Paliperidone Palmitate	41	suppressed
Aripiprazole	Aripiprazole	40	11
Eszopiclone	Eszopiclone	39	suppressed
Clozapine	Clozapine	38	suppressed
Ingrezza	Valbenazine Tosylate	37	suppressed
Vilazodone Hcl	Vilazodone Hcl	36	suppressed
Vraylar	Cariprazine Hcl	35	suppressed
Dayvigo	Lemborexant	34	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	33	suppressed
Pregabalin	Pregabalin	32	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	31	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	29	suppressed
Quviviq	Daridorexant Hcl	28	suppressed
Lithium Carbonate Er	Lithium Carbonate	27	suppressed
Carbamazepine	Carbamazepine	26	suppressed
Divalproex Sodium	Divalproex Sodium	25	suppressed
Oxazepam	Oxazepam	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	23	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	22	suppressed
Austedo	Deutetrabenazine	20	suppressed
Perphenazine	Perphenazine	19	suppressed
Doxepin Hcl	Doxepin Hcl	18	suppressed
Abilify Maintena	Aripiprazole	16	suppressed
Haloperidol	Haloperidol	16	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	16	suppressed
Asenapine Maleate	Asenapine Maleate	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	13	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	13	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	13	suppressed
Famotidine	Famotidine	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Dronabinol	Dronabinol	12	suppressed
Fanapt	Iloperidone	12	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Primidone	Primidone	11	suppressed
Triazolam	Triazolam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error